#1 Clinical Trials Search in Europe

Ly3437943 Sodium

Retatrutide, also known as LY3437943, is an investigational drug being studied in clinical trials for its potential to treat obesity and related health conditions. This article provides an overview of the ongoing research into retatrutide’s effects on weight loss, cardiovascular health, kidney function, and other outcomes in various patient populations.

Table of Contents

What is Retatrutide?

Retatrutide, also known by its code name LY3437943, is a new medication being developed by Eli Lilly and Company. It is currently undergoing clinical trials to evaluate its effectiveness in treating obesity and related health conditions[1]. Retatrutide is not yet approved for use and is still being studied to determine its safety and efficacy.

How Does Retatrutide Work?

While the exact mechanism of action is not fully described in the provided clinical trial information, Retatrutide is likely a type of medication known as a GLP-1 receptor agonist. These medications work by mimicking a hormone in your body that helps regulate blood sugar levels and appetite. By doing so, they can help reduce hunger, increase feelings of fullness, and lead to weight loss[2].

What Conditions Does Retatrutide Treat?

Based on the ongoing clinical trials, Retatrutide is being studied for its potential to treat several conditions:

  • Obesity: The primary focus of most trials is on weight loss in people with obesity or who are overweight[1].
  • Type 2 Diabetes: Some trials are investigating its effects in people with type 2 diabetes[2].
  • Knee Osteoarthritis: One study is looking at how Retatrutide might help people with knee osteoarthritis, a type of arthritis that causes pain and stiffness in the knee joint[3].
  • Cardiovascular Disease: Researchers are studying whether Retatrutide can reduce the risk of serious heart-related complications in people with obesity and established cardiovascular disease[4].
  • Chronic Kidney Disease: Some trials are investigating its potential effects on kidney function in people with chronic kidney disease[5].

How is Retatrutide Administered?

Retatrutide is administered as a subcutaneous injection. This means it’s injected just under the skin, typically once a week[1]. The medication comes in the form of a solution for injection, and it’s likely that patients would be taught how to self-administer the medication at home.

Current Clinical Trials

Several clinical trials are currently underway to study Retatrutide:

  • TRIUMPH-1: This study is looking at the effects of Retatrutide in people with obesity or who are overweight, including those with knee osteoarthritis[1].
  • TRIUMPH-2: This trial is studying Retatrutide in people with type 2 diabetes who also have obesity or are overweight[2].
  • TRIUMPH-3: This study is focusing on people with severe obesity and established cardiovascular disease[6].
  • TRIUMPH-4: This trial is specifically looking at Retatrutide’s effects on people with obesity or who are overweight and have knee osteoarthritis[3].
  • TRIUMPH-5: This study is comparing Retatrutide to another medication called tirzepatide in adults with obesity[7].
  • TRIUMPH-OUTCOMES: This large study is investigating whether Retatrutide can reduce the risk of major cardiovascular events and slow the decline of kidney function in people with obesity and cardiovascular disease or chronic kidney disease[4].

Potential Benefits of Retatrutide

Based on the ongoing clinical trials, Retatrutide may offer several potential benefits:

  • Weight loss: The primary goal of most trials is to achieve significant weight reduction[1].
  • Improved blood sugar control: For people with type 2 diabetes, Retatrutide may help manage blood sugar levels[2].
  • Reduced knee pain: In people with knee osteoarthritis, Retatrutide might help reduce pain and improve function[3].
  • Cardiovascular protection: Some studies are investigating whether Retatrutide can lower the risk of serious heart-related events[4].
  • Kidney function preservation: Researchers are studying if Retatrutide can help slow the decline of kidney function in people with chronic kidney disease[5].

Possible Side Effects

As Retatrutide is still in clinical trials, the full range of potential side effects is not yet known. However, based on similar medications, some possible side effects might include:

  • Nausea or vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain
  • Headache
  • Fatigue

It’s important to note that not everyone experiences side effects, and the benefits of the medication may outweigh the risks for many people. Always discuss potential side effects with your healthcare provider[1].

Conclusion

Retatrutide (LY3437943) is a promising new medication being studied for its potential to treat obesity and related conditions such as type 2 diabetes, knee osteoarthritis, cardiovascular disease, and chronic kidney disease. While the results of ongoing clinical trials are not yet available, the medication shows potential for significant weight loss and other health benefits. However, as with any new medication, it’s important to wait for the results of these trials to fully understand its effectiveness and safety profile. If you’re interested in participating in a clinical trial or learning more about Retatrutide, speak with your healthcare provider.

Trial Focus Key Populations Primary Outcomes
Obesity/Overweight Adults with obesity or overweight, with or without type 2 diabetes Percent change in body weight
Cardiovascular Outcomes Adults with obesity and established cardiovascular disease Time to first occurrence of major cardiovascular events
Kidney Function Adults with obesity/overweight and chronic kidney disease Change in glomerular filtration rate (GFR)
Knee Osteoarthritis Adults with obesity/overweight and knee osteoarthritis Change in WOMAC Pain subscale score and percent change in body weight
Comparison to Tirzepatide Adults with obesity Percent change in body weight compared to tirzepatide

FAQ

  • What is retatrutide (LY3437943)? Retatrutide (LY3437943) is an experimental medication being studied for its potential to treat obesity and related health conditions. It is administered as a subcutaneous injection once weekly.
  • What conditions is retatrutide being studied for? Retatrutide is being investigated for obesity, overweight, type 2 diabetes, cardiovascular disease, chronic kidney disease, and knee osteoarthritis in various clinical trials.
  • How does retatrutide work? While the exact mechanism is not fully described in the trial data, retatrutide is likely a hormone-based therapy that affects metabolism and appetite regulation to promote weight loss and potentially improve other health outcomes.
  • What are the main goals of the retatrutide clinical trials? The main goals include evaluating retatrutide's effects on body weight, cardiovascular events, kidney function, pain from knee osteoarthritis, and comparing its efficacy to other treatments like tirzepatide.
  • Who may be eligible to participate in retatrutide clinical trials? Eligibility varies by trial but generally includes adults with obesity or overweight, often with related conditions like cardiovascular disease or kidney disease. Some trials exclude those with type 1 diabetes or recent significant health events.

Ongoing Clinical Trials on Ly3437943 Sodium

  • N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +9

  • Study of Retatrutide for Patients with Obesity, Overweight, and Chronic Low Back Pain

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study Comparing Retatrutide and Tirzepatide for Weight Loss in Adults with Obesity

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland

  • Study of Retatrutide (LY3437943) for Patients with Obesity or Overweight and Knee Osteoarthritis

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Retatrutide for Patients with Obesity, Overweight, or Knee Osteoarthritis

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Hungary Poland Romania Spain

  • Study on Retatrutide and Placebo for Kidney Function in Overweight or Obese Patients with Chronic Kidney Disease, with or without Type 2 Diabetes

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study of Retatrutide for Patients with Type 2 Diabetes and Obesity or Overweight

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Romania Spain

  • Study on the Effects of Retatrutide for Patients with Severe Obesity and Cardiovascular Disease

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Hungary Poland Slovakia Spain

Glossary

  • Retatrutide: An investigational drug (also called LY3437943) being studied as a potential treatment for obesity and related health conditions.
  • Body Mass Index (BMI): A measure of body fat based on height and weight. BMI is often used to determine if someone is overweight or obese.
  • Cardiovascular Disease (CVD): A group of disorders affecting the heart and blood vessels, including conditions like heart attacks and strokes.
  • Chronic Kidney Disease (CKD): Long-term damage to the kidneys that can affect their ability to filter waste from the blood.
  • Type 2 Diabetes: A chronic condition affecting how the body processes blood sugar (glucose).
  • Osteoarthritis: A type of joint disease caused by breakdown of joint cartilage and underlying bone, often affecting the knees.
  • WOMAC Pain Subscale: Western Ontario and McMaster Universities Osteoarthritis Index, a measure used to assess pain in osteoarthritis patients.
  • Glomerular Filtration Rate (GFR): A measure of how well the kidneys are filtering waste from the blood.
  • Subcutaneous Injection: An injection given into the fatty tissue just beneath the skin.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-retatrutide-for-patients-with-obesity-overweight-or-knee-osteoarthritis/
  2. http://clinicaltrials.eu/trial/study-of-retatrutide-for-patients-with-type-2-diabetes-and-obesity-or-overweight/
  3. http://clinicaltrials.eu/trial/study-of-retatrutide-ly3437943-for-patients-with-obesity-or-overweight-and-knee-osteoarthritis/
  4. http://clinicaltrials.eu/trial/study-on-the-effects-of-retatrutide-on-heart-and-kidney-health-in-adults-with-obesity/
  5. http://clinicaltrials.eu/trial/study-on-retatrutide-and-placebo-for-kidney-function-in-overweight-or-obese-patients-with-chronic-kidney-disease-with-or-without-type-2-diabetes/
  6. http://clinicaltrials.eu/trial/study-on-the-effects-of-retatrutide-for-patients-with-severe-obesity-and-cardiovascular-disease/
  7. http://clinicaltrials.eu/trial/study-comparing-retatrutide-and-tirzepatide-for-weight-loss-in-adults-with-obesity/